CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of pancreatic cancer.
  
  OVERVIEW OF ACTIVITY
  Pancreatic cancer is the fourth most common cause of cancer-related death among US men and women. The overwhelming majority (approximately 90%) of pancreatic cancers are ductal adenocarcinomas, and many patients diagnosed with pancreatic adenocarcinoma (PAD) do not exhibit distinctive symptoms until the disease has reached an advanced stage. For all stages of PAD the combined 1-year survival rate for patients who do not receive surgery is approximately 29%, and the 5-year rate is an appalling 7%. Published results from ongoing trials have led to the emergence of new therapeutic targets and regimens, and the poor clinical course for so many patients with progressive PAD mandates the consideration of these approaches. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. This CME program was developed from the proceedings of a satellite symposium held during the 2019 Gastrointestinal Cancers Symposium. It explores the most significant therapeutic advances in the field of pancreatic cancer by using the perspectives of leading experts on challenging cases and questions submitted by community oncologists to frame a discussion of how this information has aided in the refinement of current clinical practice and ongoing research. This activity will help medical oncologists and other allied healthcare professionals find answers to the individualized questions and concerns they frequently encounter, and in turn it will help them to provide high-quality cancer care.
  
  LEARNING OBJECTIVES

  • Develop an evidence-based strategy for the treatment of resectable or borderline-resectable PAD, exploring the role of neoadjuvant and adjuvant chemotherapy and/or radiation therapy.
  • Consider patient and disease characteristics and available clinical trial data in the selection and sequencing of systemic therapy for locally advanced or metastatic PAD.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of approved systemic regimens for the management of locally advanced or metastatic PAD and thus to support quality of life and continuation of therapy.
  • Recall available and emerging data with investigational agents currently in clinical testing for PAD, and where applicable refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Andrew E Hendifar, MD
  Medical Director, Pancreatic Cancer
  Gastrointestinal and Neuroendocrine Malignancies
  Cedars-Sinai Medical Center
  Los Angeles, California
  
  Advisory Committee: Ipsen Biopharmaceuticals Inc; Consulting Agreements: Ipsen Biopharmaceuticals Inc, Novartis; Contracted Research: Halozyme Inc, Ipsen Biopharmaceuticals Inc.
  
  Eileen M O’Reilly, MD
  Winthrop Rockefeller Chair in Medical Oncology
  Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
  Gastrointestinal Oncology Service
  Associate Director
  David M Rubenstein Center for Pancreatic Cancer
  Attending Physician, Member
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Cornell Medical College
  New York, New York
  
  Consulting Agreements: 3DMedcare, Agios Pharmaceuticals Inc, Alignmed, Amgen Inc, Antengene, Aptus Clinical, Arbutus Biopharma, ASLAN Pharmaceuticals, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, BioLineRx, Boston Scientific Corporation, BridgeBio, Bristol-Myers Squibb Company, CARsgen Therapeutics, CASI Pharmaceuticals, Celgene Corporation, Cipla Limited, CytomX Therapeutics, Daiichi Sankyo Inc, Debiopharm Group, Delcath Systems Inc, Eisai Inc, Exelixis Inc, Genoscience Pharma, Gilead Sciences Inc, Halozyme Inc, Hengrui Therapeutics Inc, Incyte Corporation, Inovio Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kyowa Hakko Kirin Co Ltd, LAM, Lilly, Loxo Oncology, Merck, MINAPHARM Pharmaceuticals, NewLink Genetics Corporation, Novella Clinical, Onxeo, PCI Biotech, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, PharmaCyte Biotech, Pieris Pharmaceuticals, QED Therapeutics, RedHill, Sanofi Genzyme, Servier, Silenseed Ltd, SillaJen, Sobi, Targovax, twoXAR, Vicus Therapeutics, Yakult Pharmaceutical Industry CO LTD, Yiviva; Contracted Research: Acta Biologica, Agios Pharmaceuticals Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Bristol-Myers Squibb Company, CASI Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech, Halozyme Inc, Incyte Corporation, Lilly, MabVax, Novartis, OncoQuest Inc, Polaris Group, Puma Biotechnology Inc, QED Therapeutics, Roche Laboratories Inc.
  
  Philip A Philip, MD, PhD
  Kathryn Cramer Endowed Chair in Cancer Research
  Professor of Oncology and Pharmacology
  Leader, GI and Neuroendocrine Oncology
  Vice President of Medical Affairs
  Karmanos Cancer Institute
  Wayne State University
  Detroit, Michigan
  
  Advisory Committee: AbbVie Inc, Biolinx, Caris Life Sciences, Celgene Corporation, Eisai Inc, Forty Seven Inc, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Lilly, Merck, Novartis, Rafael Pharmaceuticals Inc, Taiho Oncology Inc; Consulting Agreements: AbbVie Inc, Celgene Corporation, Lilly, Merck, Rafael Pharmaceuticals Inc; Contracted Research: AAA Pharmaceutical, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Biolinx, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Forty Seven Inc, Gilead Sciences Inc, Halozyme Inc, Incyte Corporation, Lilly, Merck, Novocure, QED Therapeutics, Taiho Oncology Inc, Tyme Technologies Inc; Data and Safety Monitoring Board/Committee: ASLAN Pharmaceuticals, Blueprint Medicines, Erytech Pharma, Lexicon Pharmaceuticals Inc; Speakers Bureau: Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Merck.
  
  Margaret A Tempero, MD
  Director, UCSF Pancreas Center
  The Rombauer Family Distinguished Professorship in Pancreas Cancer
  Clinical and Translational Science
  Leader, Pancreas Cancer Program
  Professor of Medicine, Division of Hematology and Oncology
  University of California, San Francisco
  San Francisco, California
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Cancer Prevention Research Institute of Texas, Immunovia; Consulting Agreements: Advance Medical, Astellas Pharma Global Development Inc, BioPharm Communications, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital, Merck; Contracted Research: FibroGen, Gossamer Bio, Halozyme Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Celgene Corporation, Halozyme Inc and Ipsen Biopharmaceuticals Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: April 2019
  Expiration date: April 2020